Skip to main content
Top

30-01-2025 | Nephrotic Syndrome | Review

Past and future in vitro and in vivo approaches toward circulating factors and biomarkers in idiopathic nephrotic syndrome

Authors: Mara S. Guaragna, Fernanda M. S. Casimiro, Patrícia Varela, Luciana de S. Feltran, Andreia Watanabe, Precil D. M. M. Neves, João B. Pesquero, Vera M. S. Belangero, Paulo C. K. Nogueira, Luiz F. Onuchic

Published in: Pediatric Nephrology

Login to get access

Abstract

Predicting the risks of progression to chronic kidney disease (CKD) stage 5 in idiopathic nephrotic syndrome (NS) and recurrence of the disease (rNS) following kidney transplantation (KT) is a key assessment to provide essential management information. NS has been categorized etiologically as genetic and immune-based. A genetic cause can be identified in ~ 30% of children with steroid-resistant NS (SRNS), a finding associated with a very low risk of rNS following KT. In immune-based NS, clinical overlap is observed among steroid-sensitive NS, secondary-resistant NS, and SRNS not associated with disease-causing genetic variants (non-monogenic SRNS). While ~ 50% of SRNS patients with no identified monogenic disease respond to intensified immunosuppressive treatments, the ones that do not respond to this therapy have a high risk of progression to CKD stage 5 and post-KT rNS. Secondary-resistant patients who progress to CKD stage 5 display the highest risk of post-KT rNS. The proposed shared underlying mechanism of the immune-based NS associated with post-KT rNS is based on a systemic circulating factor (CF) that affects glomerular permeability by inducing foot process effacement and focal segmental glomerulosclerosis. However, identifying patients without a detected genetic form who will recur post-KT is a major challenge. Extensive efforts, therefore, have been made to identify CFs and biomarkers potentially capable of predicting the risk of progression to CKD stage 5 and post-KT rNS. This review discusses the in vitro and in vivo approaches employed to date to identify and characterize potential CFs and CF-induced biomarkers of recurrent NS and offers an assessment of their potential to improve outcomes of KT in this patient population.

Graphical abstract

Appendix
Available only for authorised users
Literature
9.
go back to reference Lagrue G, Branellec A, Niaudet P et al (1991) Transmission of nephrotic syndrome to two neonates. Spontaneous regression. Presse Med 20:255–257PubMed Lagrue G, Branellec A, Niaudet P et al (1991) Transmission of nephrotic syndrome to two neonates. Spontaneous regression. Presse Med 20:255–257PubMed
13.
go back to reference Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22:32–38PubMed Zimmerman SW (1984) Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation. Clin Nephrol 22:32–38PubMed
18.
go back to reference Bakker WW, van Baller JF, LW, (1988) A kallikrein-like molecule and plasma vasoactivity in minimal change disease. Increased turnover in relapse versus remission. Contrib Nephrol 67:31–36CrossRefPubMed Bakker WW, van Baller JF, LW, (1988) A kallikrein-like molecule and plasma vasoactivity in minimal change disease. Increased turnover in relapse versus remission. Contrib Nephrol 67:31–36CrossRefPubMed
Metadata
Title
Past and future in vitro and in vivo approaches toward circulating factors and biomarkers in idiopathic nephrotic syndrome
Authors
Mara S. Guaragna
Fernanda M. S. Casimiro
Patrícia Varela
Luciana de S. Feltran
Andreia Watanabe
Precil D. M. M. Neves
João B. Pesquero
Vera M. S. Belangero
Paulo C. K. Nogueira
Luiz F. Onuchic
Publication date
30-01-2025
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-024-06643-8

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now